section name header

Indications

BEERS REMS

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: edema, HF, hypertension, MI, vasculitis.

Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), EXFOLIATIVE DERMATITIS, sweating, photosensitivity, pruritus, rash, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS.

EENT: abnormal vision, tinnitus.

GI: abdominal pain, diarrhea, anorexia, constipation, dry mouth, dyspepsia, flatulence, gastritis, gastroenteritis, GI BLEEDING, liver enzymes, nausea, stomatitis, vomiting.

GU: albuminuria, azotemia, interstitial nephritis.

Hemat: prolonged bleeding time.

Metab: appetite, weight gain.

Neuro: agitation, anxiety, confusion, depression, dizziness, drowsiness, fatigue, headache, insomnia, malaise, paresthesia, STROKE, tremor, weakness.

Resp: dyspnea, hypersensitivity pneumonitis.
Misc: (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)HYPERSENSITIVITY REACTIONS .

Interactions

Drug-Drug:

Availability

(Generic available)

Route/Dosage

US Brand Names

Relafen, Relafen DS

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: antirheumatics, nonopioid analgesics

Pharmacologic Classification:

Pharmacokinetics

Absorption: Nabumetone (a prodrug) is 80% absorbed after oral administration; 35% is rapidly converted to 6-methoxy-2-naphthylacetic acid (6-MNA), which is the active drug.

Distribution: Unknown.

Protein Binding: >99%.

Metabolism/Excretion: 6-MNA is metabolized by the liver to inactive compounds.

Half-life: 24 hr ( in severe renal impairment).

Time/Action Profile

(analgesia/anti-inflammatory effects)

ROUTEONSETPEAKDURATION
PO1–2 daysfew days–2 wk12–24 hr

Patient/Family Teaching

Pronunciation

na-BYOO-me-tone